Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Bell Global Emerging Companies Fund Ned Bell, Joel Connell, Matt Saddington | “Additionally, we initiated a position in Organo. Organo is a Japanese water treatment engineering company that designs, constructs and maintains pure and ultrapure water facilities. The company is a direct beneficiary of the AI-driven capex cycle: ultrapure water is mission-critical to chip manufacturing. Organo not only builds and operates fab water systems but also provides wafer cleaning solutions, giving it a growing recurring revenue base alongside its engineering backlog. Our conviction was further strengthened by a recent meeting with the CEO, from which we came away confident that guidance (particularly on revenue growth) is conservatively framed. Notably, the company's mid-term plan through to 2031 (anchored to a ¥260bn revenue target) assumes no meaningful new client wins, despite memory manufacturers in Taiwan already approaching Organo for ultrapure water solutions. Management indicated that capacity, rather than demand, is currently the primary constraint, reflecting its commitment to servicing TSMC's ongoing expansion. We view sell-side forecasts of approximately 14% revenue growth in FY27, fading to just 4% by FY29, as conservative. This appears inconsistent with the pipeline of large semiconductor projects, together with opportunities in pharmaceuticals and emerging markets such as India. With demand visibility underpinned by structural semiconductor investment, we saw an attractive opportunity to own a critical-infrastructure supplier to the AI buildout, at a valuation that does not reflect the optionality in its order book. Compared with many AI beneficiaries trading on elevated valuations, we believe Organo offers the potential for both earnings upgrades and valuation expansion as its growth opportunities become better reflected in market expectations.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
